Levofloxacin after sudden stroke to improve safety and recovery
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether the antibiotic levofloxacin can be given soon after an acute ischemic stroke to improve outcomes and monitor side effects. It’s for people with a moderate stroke severity who are not having certain emergency treatments or infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 75 years old.
- Your stroke is an acute ischemic stroke (a blockage), with stroke severity NIHSS between 5 and 15.
- Before this stroke, you were functioning independently (mRS 1 or less).
- You can give informed consent and agree to follow-up for the study.
- You have NOT had a mini-stroke (TIA) or emergency blood-flow procedures like IV thrombolysis or emergency clot removal.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the antibiotic levofloxacin to standard IV clot-busting treatment is safe and improves outcomes after an acute ischemic stroke. It may help by reducing complications related to infection or inflammation, but you must meet specific heart, liver, kidney, and medication-safety rules.
This trial tests whether a drug called urinary kallidinogenase can help people who have had a stroke caused by a blocked artery in the brain. The drug is given within 48 hours of the stroke, and the study hopes to see if it improves recovery and reduces disability.
This trial tests a drug called Aleeto in people who have had an acute ischemic stroke (a stroke caused by a blocked blood vessel) within the last 72 hours. It aims to see if Aleeto can improve recovery and reduce disability.
This trial tests a medication called tirofiban given intravenously after standard thrombolysis to see if it improves recovery in people with acute ischemic stroke. It is for those whose symptoms have not improved or are getting worse after initial treatment.
This Phase 2 study tests LT3001 to improve recovery after an acute ischemic stroke (a stroke caused by blocked blood flow). It is designed for people who can be treated within 24 hours of symptom onset and who meet specific safety and health requirements.
This trial tests whether MT200605 can help people who recently had an ischemic stroke (a type of stroke caused by a blocked blood vessel). The drug is given within 24 hours of symptoms starting, and you may join even if you received clot-busting treatment already.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.